Targeting CXCR4 to suppress glioma‐initiating cells and chemoresistance in glioma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting CXCR4 to suppress glioma‐initiating cells and chemoresistance in glioma

Published:2022-06-22 Issue:9 Volume:46 Page:1519-1529
ISSN:1065-6995
Container-title:Cell Biology International
language:en
Short-container-title:Cell Biology International

Author:

Wu Yao¹,Hu Yu²,Tang Lingli³,Yin Senlin²,Lv Liang²,Zhou Peizhi²^ORCID

Affiliation:

1. Department of Neurosurgery Chongqing University Three Gorges Hospital Chongqing China

2. Department of Neurosurgery West China Hospital of Sichuan University Chengdu China

3. Department of Neurology Chongqing University Three Gorges Hospital Chongqing China

Funder

Southwest Medical University

Department of Science and Technology of Sichuan Province

Publisher

Wiley

Subject

Cell Biology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cbin.11836

Reference48 articles.

1. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines

2. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer

3. A Shifty Target: Tumor-Initiating Cells and Their Metabolism

4. PREFERENTIAL EXPRESSION OF CHEMOKINE RECEPTOR CXCR4 BY HIGHLY MALIGNANT HUMAN GLIOMAS AND ITS ASSOCIATION WITH POOR PATIENT SURVIVAL

5. Further understanding of the pathology of glioma: implications for the clinic

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?;Neuro-Oncology;2024-02-23

2. Predictive value of expression of the CXCR4/Akt signaling pathway in the peripheral blood for brain glioma;Revista Romana de Medicina de Laborator;2024-01-01

3. Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies;Cells;2023-03-08

4. Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology;Frontiers in Pharmacology;2022-11-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3